Acurx Pharmaceuticals Inc
Company Profile
Business description
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Contact
259 Liberty Avenue
Staten IslandNY10305
USAT: +1 917 533-1469
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Guzman Y Gomez’s outlook unchanged despite strong update
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.40 | 28.60 | -0.32% |
| CAC 40 | 7,915.15 | 42.04 | 0.53% |
| DAX 40 | 25,232.62 | 65.99 | -0.26% |
| Dow JONES (US) | 51,621.48 | 48.62 | -0.09% |
| FTSE 100 | 10,831.52 | 106.66 | 0.99% |
| HKSE | 24,062.72 | 251.45 | -1.03% |
| NASDAQ | 26,692.87 | 511.51 | -1.88% |
| Nikkei 225 | 64,425.95 | 3,318.34 | -4.90% |
| NZX 50 Index | 13,832.80 | 72.41 | 0.53% |
| S&P 500 | 7,718.94 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,719.70 | 8.20 | -0.09% |
| SSE Composite Index | 3,707.48 | 59.75 | -1.59% |